Loss of p38δ mitogen-activated protein kinase expression promotes oesophageal squamous cell carcinoma proliferation, migration and anchorage-independent growth

O'Callaghan,Carol; Fanning,Liam J.; Houston,Aileen; Barry,Orla  P.

doi:10.3892/ijo.2013.1968

Loss of p38δ mitogen-activated protein kinase expression promotes oesophageal squamous cell carcinoma proliferation, migration and anchorage-independent growth

Authors:
- Carol O'Callaghan
- Liam J. Fanning
- Aileen Houston
- Orla P. Barry
View Affiliations

Affiliations: Department of Pharmacology and Therapeutics, University College Cork, Ireland, Department of Medicine, University College Cork, Ireland
Published online on: May 29, 2013 https://doi.org/10.3892/ijo.2013.1968
Pages: 405-415
Copyright: © O'Callaghan et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oesophageal cancer is an aggressive tumour which responds poorly to both chemotherapy and radiation therapy and has a poor prognosis. Thus, a greater understanding of the biology of oesophageal cancer is needed in order to identify novel therapeutic targets. Among these targets p38 MAPK isoforms are becoming increasingly important for a variety of cellular functions. The physiological functions of p38α and -β are now well documented in contrast to -γ and -δ which are comparatively under-studied and ill-defined. A major obstacle to deciphering the role(s) of the latter two p38 isoforms is the lack of specific chemical activators and inhibitors. In this study, we analysed p38 MAPK isoform expression in oesophageal cancer cell lines as well as human normal and tumour tissue. We observed specifically differential p38δ expression. The role(s) of p38δ and active (phosphorylated) p38δ (p-p38δ) in oesophageal squamous cell carcinoma (OESCC) was delineated using wild-type p38δ as well as active p-p38δ, generated by fusing p38δ to its upstream activator MKK6b(E) via a decapeptide (Gly-Glu)5 linker. OESCC cell lines which are p38δ-negative (KE-3 and -8) grew more quickly than cell lines (KE-6 and -10) which express endogenous p38δ. Re-introduction of p38δ resulted in a time-dependent decrease in OESCC cell proliferation which was exacerbated with p-p38δ. In addition, we observed that p38δ and p-p38δ negatively regulated OESCC cell migration in vitro. Finally both p38δ and p-p38δ altered OESCC anchorage-independent growth. Our results suggest that p38δ and p-p38δ have a role in the suppression of OESCC. Our research may provide a new potential target for the treatment of oesophageal cancer.

View Figures

View References

1.	Kayani B, Zacharakis E, Ahmed K and Hanna GB: Lymph node metastases and prognosis in oesophageal carcinoma - a systematic review. Eur J Surg Oncol. 37:747–753. 2011. View Article : Google Scholar : PubMed/NCBI
2.	Enzinger PC and Mayer RJ: Esophageal cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
3.	Almhanna K and Strosberg JR: Multimodality approach for locally advanced esophageal cancer. World J Gastroenterol. 18:5679–5687. 2012. View Article : Google Scholar : PubMed/NCBI
4.	Thallinger CM, Kiesewetter B, Raderer M and Hejna M: Preand postoperative treatment modalities for esophageal squamous cell carcinoma. Anticancer Res. 32:4609–4627. 2012.PubMed/NCBI
5.	Klein CA and Stoecklein NH: Lessons from an aggressive cancer: evolutionary dynamics in esophageal cancer. Cancer Res. 69:5285–5288. 2009. View Article : Google Scholar : PubMed/NCBI
6.	Bird-Lieberman EL and Fitzgerald RC: Early diagnosis of oesophageal cancer. Br J Cancer. 101:1–6. 2009. View Article : Google Scholar
7.	Sanz V, Arozarena I and Crespo P: Distinct carboxy-termini confer divergent characteristics to the mitogen-activated protein kinase p38α and its splice isoform Mxi2. FEBS Lett. 474:169–174. 2000.PubMed/NCBI
8.	Raman M, Chen W and Cobb MH: Differential regulation and properties of mapks. Oncogene. 26:3100–3112. 2007. View Article : Google Scholar : PubMed/NCBI
9.	Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, Kenner L, Komnenovic V, Scheuch H, Beug H and Wagner EF: P38alpha suppresses normal and cancer cell proliferation by antagonizing the jnk-c-jun pathway. Nat Genet. 39:741–749. 2007. View Article : Google Scholar : PubMed/NCBI
10.	Ono K and Han J: The p38 signal transduction pathway: activation and function. Cell Signal. 12:1–13. 2000. View Article : Google Scholar
11.	Zarubin T and Han J: Activation and signaling of the p38 MAP kinase pathway. Cell Res. 15:11–18. 2005. View Article : Google Scholar : PubMed/NCBI
12.	Kyriakis JM and Ayruch J: Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol Rev. 92:689–737. 2012.PubMed/NCBI
13.	Cuenda A and Rousseau S: p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta. 1773:1358–1375. 2007. View Article : Google Scholar : PubMed/NCBI
14.	Eyers PA, Craxton M, Morrice N, Cohen P and Goedert M: Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. Chem Biol. 5:321–328. 1998. View Article : Google Scholar : PubMed/NCBI
15.	Yamana H, Kakegawa T, Tanaka T, Higaki K, Fujii T and Tou U: Experimental studies on immunotargeting therapy for esophageal carcinoma. Gan To Kagaku Ryoho. 21:755–760. 1994.PubMed/NCBI
16.	Tsukahara T, Nabeta Y, Kawaguchi S, Ikeda H, Sato Y, Shimozawa K, Ida K, Asanuma H, Hirohashi Y, Torigoe T, Hiraga H, Nagoya S, Wada T, Yamashita T and Sato N: Identification of human autologous cytotoxic T-lymphcyte-defined osteosarcoma gene that encodes a transcriptional regulator, papillomavirus binding factor. Cancer Res. 64:5442–5448. 2004. View Article : Google Scholar
17.	Nakao M, Yamann H, Imai Y, Toh Y, Toh U, Kimura A, Yanoma S, Kakegawa T and Hoir K: HLA A2601-restricted CTLs recognize a peptide antigen expressed on squamous cell carcinoma. Cancer Res. 55:4248–4252. 1995.PubMed/NCBI
18.	Barry OP, Mullan B, Sheehan D, Kazanietz MG, Shanahan F, Collins JK and O’Sullivan GC: Constitutive ERK1/2 activation in esophagogastric rib bone marrow micrometastatic cells is MEK-independent. J Biol Chem. 276:15537–15546. 2001. View Article : Google Scholar : PubMed/NCBI
19.	Pramanik R, Qi X, Borowicz S, Choubey D, Schultz RM, Han J and Chen G: p38 isoforms have opposite effects on AP-1-dependent transcription through regulation of c-Jun. The determinant roles of the isoforms in the p38 MAPK signal specificity. J Biol Chem. 278:4831–4839. 2003. View Article : Google Scholar
20.	Zheng C, Xiang J, Hunter T and Lin A: The JNKK2-JNK1 fusion protein acts as a constitutively active c-Jun Kinase that stimulates c-Jun transcription activity. J Biol Chem. 274:28966–28971. 1999. View Article : Google Scholar : PubMed/NCBI
21.	O’Sullivan GC, Tangney M, Casey G, Ambrose M, Houston A and Barry OP: Modulation of p21-activated kinase 1 alters the behavior of renal cell carcinoma. Int J Cancer. 121:1930–1940. 2007.PubMed/NCBI
22.	Chen L, Zhang JJ and Huang XY: cAMP inhibits cell migration by interfering with Rac-induced lamellipodium formation. J Biol Chem. 283:13799–13805. 2008. View Article : Google Scholar : PubMed/NCBI
23.	Adhikary G, Chew YC, Reece EA and Eckert RL: PKC-delta and -eta, MEKK-1, MEK-6, MEK-3 and p38-delta are essential mediators of the response of normal human epidermal keratinocytes to differentiating agents. J Invest Dermatol. 130:2017–2030. 2010. View Article : Google Scholar
24.	Cargnello M and Roux P: Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. 75:50–83. 2011. View Article : Google Scholar : PubMed/NCBI
25.	Wagner EF and Nebreda ÁR: Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 9:537–549. 2009. View Article : Google Scholar : PubMed/NCBI
26.	Ambrose M, Ryan A, O’Sullivan GC, Dunne C and Barry OP: Induction of apoptosis in renal cell carcinoma by reactive oxygen species: involvement of extracellular signal-regulated kinase 1/2, p38delta/gamma, cyclooxygenase-2 down-regulation and translocation of apoptosis-inducing factor. Mol Pharmacol. 69:1879–1890. 2006. View Article : Google Scholar
27.	Remy G, Risco AM, Iñesta-Vaquera FA, González-Terán B, Sabio G, Davis RJ and Cuenda A: Differential activation of p38MAPK isoforms by MKK6 and MKK3. Cell Signal. 22:660–667. 2010. View Article : Google Scholar : PubMed/NCBI
28.	Reid TD, Sanyaolu LN, Chan D, Williams GT and Lewis WG: Relative prognostic value of TNM7 vs TNM6 in staging oesophageal cancer. Br J Cancer. 105:842–846. 2011. View Article : Google Scholar : PubMed/NCBI
29.	Junttila MR, Ala-aho R, Jokilehto T, Peltonen J, Kallajoki M, Grenman R, Jaakkola P, Westermarck J and Kähäri V-M: p38α and p38δ mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells. Oncogene. 26:5267–5279. 2007.
30.	Efimova T, Broome A-M and Eckert RL: Protein kinase Cδ regulates keratinocyte death and survival by regulating activity and subcellular localization of a p38δ-extracellular signal-regulated kinase 1/2 complex. Mol Cell Biol. 24:8167–8183. 2004.
31.	Efimova T, Broome AM and Eckert RL: A regulatory role for p38δ MAPK in keratinocyte differentiation. Evidence for p38δ-ERK1/2 complex formation. J Biol Chem. 278:34277–34285. 2003.
32.	Li Q, Zhang N, Zhang D, Wang Y, Lin T, Wang Y, Zhou H, Ye Z, Zhang F, Lin S-C and Han J: Determinants that control the distinct subcellular localization of p38α-PRAK and p38β-PRAK complexes. J Biol Chem. 283:11014–11023. 2008.PubMed/NCBI
33.	Fan L, Yang X, Du J, Marshall M, Blanchard K and Ye X: A novel role of p38α MAPK in mitotic progression independent of its kinase activity. Cell Cycle. 4:1616–1624. 2005.
34.	Tang J, Qi X, Mercola D, Han J and Chen G: Essential role of p38γ in K-Ras transformation independent of phosphorylation. J Biol Chem. 280:23910–23917. 2005.
35.	Del Barco Barrantes I and Nebreda AR: Roles of p38 MAPKs in invasion and metastasis. Biochem Soc Trans. 40:79–84. 2012.PubMed/NCBI
36.	Izzo JG, Luthra R, Sims-Mourtada J, Chao KSC, Lee JH, Wu T-T, Correa AM, Luthra M, Aggarwal B, Hung M-C and Ajani JA: Emerging molecular targets in esophageal cancers. Gastrointest Cancer Res. 1:S3–S6. 2007.PubMed/NCBI
37.	Bulavin DV and Fornace AJ: p38 MAP kinases’s emerging role as a tumour suppressor. Adv Cancer Res. 92:95–118. 2004.
38.	Hui L, Bakiri L, Stepniak E and Wagber EF: p38α a supressor of cell proliferation and tumorigenesis. Cell Cycle. 6:2429–2433. 2007.
39.	Ventura JJ, Tenbaum S, Perdiguero E, Huth M, Guerra C, Barbacid M, Pasparakis M and Nebreda AR: p38α MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat Genet. 39:750–758. 2007.
40.	Schindler EM, Hindes A, Gribben EL, Burns CJ, Yin Y, Lin M-H, Owen RJ, Longmore GD, Kissling GE, Arthur JSC and Efimova T: p38δ mitogen-activated protein kinase is essential for skin tumor development in mice. Cancer Res. 69:4648–4655. 2009.
41.	Cerezo-Guisado MI, Del Reino P, Remy G, Kuma Y, Arthur JSC, Gallego-Ortega D and Cuenda A: Evidence of p38γ and p38δ involvement in cell transformation processes. Carcinogenesis. 32:1093–1099. 2011.
42.	Sundaramurthy P, Gakkhar S and Sowdhamini R: Analysis of the impact of ERK5, JNK and p38 kinase cascades on each other: a systems approach. Bioinformation. 3:244–249. 2009. View Article : Google Scholar : PubMed/NCBI
43.	Ambrosino C, Mace G, Galban S, Fritsch C, Vintersten k, Black E, Gorospe M and Nebreda AR: Negative feedback regulation of MKK6 mRNA stability by p38α mitogen-activated protein kinase. Mol Cell Biol. 23:370–381. 2003.PubMed/NCBI
44.	Coulthars LR, White DE, Jones DL, McDermott MF and Burchill SA: p38^MAPK: stress responses from molecular mechanisms to therapeutics. Trends Mol Med. 15:369–379. 2009.
45.	Gaestel M and Kracht M: Peptides as signalling inhibitors for mammalian MAP kinase cascades. Curr Pharm Des. 15:2471–2480. 2009. View Article : Google Scholar : PubMed/NCBI